Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): MAIC.
Read here:Â https://meetinglibrary.asco.org/record/188306/abstract